Duloxetine on Bone Metabolism

Cukurova University102 enrolled

Overview

The aim of the study was to determine the effect of duloxetine as monotherapy on biochemical markers and bone mineral density.

51 patients diagnosed with chronic pain or fibromyalgia syndrome who were using duloxetine for at least 3 months and age and sex matched 51 healthy individuals were recruited for this cross-sectional study. Bone mineral density of both groups were measured by dual energy x ray absorbsiometry(DXA), bone biochemical markers, serum calcium, and vitamin D levels were investigated.

Study Type

OBSERVATIONAL

Enrollment

102

Conditions

Chronic Pain Fibromyalgia

Interventions

DuloxetineDRUG

Patients who use duloxetine for chronic pain or fibromyalgia

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * \>18 years or \<50 years * patients using duloxetine for at least 3 months due to chronic pain or fibromyalgia Exclusion Criteria: * postmenopausal women * clinical conditions which cause secondary osteoporosis * patients using medication that cause secondary osteoporosis * pregnancy and malignity

Locations (1)

Çukurova Üniversitesi

Adana, Turkey (Türkiye)

RECRUITING

Outcomes

Primary Outcomes

DXA

Bone mineral densitomtry

Time frame: 3 months

CTX

C-terminal telopeptide

Time frame: 3 months

Osteocalcin

Time frame: 3 months

25-OH VITD3

25-hydroxyvitamin D3

Time frame: 3 months

Central Contacts

Bayram Kelle, Assoc. Prof.

CONTACT

903223386060-3161 bayramkelle@yahoo.com

Bayram Kelle, Assoc. Prof

CONTACT

903223386060-3161 bayramkelle@yahoo.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.